This federal contract award to Advanced Accelerator Applications USA Inc., a subsidiary of Novartis, is for the delivery of six branded nuclear medicine products approved by the FDA, including LUTATHERA and PLUVICTO. The $498,438.38 firm-fixed-price purchase order has a completion date of December 4, 2025 and was awarded on December 4, 2024 by the Defense Health Agency (DHA), a defense agency. The contract is not set aside for small businesses. Advanced Accelerator Applications USA Inc. is a large, foreign-owned, for-profit manufacturer of radiopharmaceuticals and nuclear medicine products, and this award is part of the company's existing Indefinite Delivery Vehicles (IDVs) and Blanket Purchase Agreements (BPAs) with federal agencies such as the Department of Veterans Affairs and the National Institutes of Health for the procurement of specialized nuclear medicine products.
Generated 3/5/25, 10:14 AM